Roth MKM Remains a Buy on Longeveron (LGVN)
TipRanks (Fri, 15-May 7:17 AM ET)
Longeveron Earnings Call: Trial Milestones Amid FDA Hurdles
TipRanks (Thu, 14-May 8:14 PM ET)
TipRanks (Thu, 14-May 6:30 AM ET)
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Globe Newswire (Wed, 13-May 4:05 PM ET)
Globe Newswire (Mon, 11-May 9:10 AM ET)
Globe Newswire (Fri, 8-May 4:05 PM ET)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
Globe Newswire (Tue, 5-May 4:15 PM ET)
Globe Newswire (Thu, 23-Apr 6:15 AM ET)
Globe Newswire (Wed, 8-Apr 9:15 AM ET)
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
Globe Newswire (Wed, 18-Mar 11:30 AM ET)
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Longeveron - Class A trades on the NASDAQ stock market under the symbol LGVN.
As of May 19, 2026, LGVN stock price climbed to $0.68 with 12,221 million shares trading.
LGVN has a beta of -0.57, meaning it tends to be less sensitive to market movements. LGVN has a correlation of 0.00 to the broad based SPY ETF.
LGVN has a market cap of $21.18 million. This is considered a Sub-Micro Cap stock.
Last quarter Longeveron - Class A reported $398,000 in Revenue and -$.19 earnings per share. This beat revenue expectation by $64,800 and met earnings estimates .
In the last 3 years, LGVN traded as high as $40.00 and as low as $.48.
The top ETF exchange traded funds that LGVN belongs to (by Net Assets): VTI, VXF.
LGVN has underperformed the market in the last year with a price return of -52.1% while the SPY ETF gained +24.8%. However, in the short term, LGVN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +21.1% vs +7.2% return in SPY. But in the last 2 weeks, LGVN shares have been beat by the market, returning -21.2% compared to an SPY return of +2.2%.
LGVN support price is $.65 and resistance is $.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGVN shares will trade within this expected range on the day.